Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNYSE:CBM
CUSIP13201110
Phone201-804-3000
Debt
Debt-to-Equity RatioN/A
Current Ratio5.11%
Quick Ratio3.44%
Price-To-Earnings
Trailing P/E Ratio17.26
Forward P/E Ratio19.47
P/E Growth1.3
Sales & Book Value
Annual Sales$534.46 million
Price / Sales3.36
Cash Flow$4.1916 per share
Price / Cash13.05
Book Value$16.62 per share
Price / Book3.29
Profitability
EPS (Most Recent Fiscal Year)$3.17
Net Income$102.45 million
Net Margins19.17%
Return on Equity22.42%
Return on Assets15.91%
Miscellaneous
Employees1,228
Outstanding Shares32,850,000
Cambrex (NYSE:CBM) Frequently Asked Questions
What is Cambrex's stock symbol?
Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."
How were Cambrex's earnings last quarter?
Cambrex Co. (NYSE:CBM) issued its quarterly earnings results on Thursday, February, 8th. The biotechnology company reported $1.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.10 by $0.17. The biotechnology company earned $182.28 million during the quarter, compared to analyst estimates of $181.39 million. Cambrex had a net margin of 19.17% and a return on equity of 22.42%. Cambrex's quarterly revenue was up 2.5% compared to the same quarter last year. During the same period last year, the business earned $1.23 EPS. View Cambrex's Earnings History.
When is Cambrex's next earnings date?
What guidance has Cambrex issued on next quarter's earnings?
Cambrex issued an update on its FY18 earnings guidance on Thursday, February, 8th. The company provided earnings per share guidance of $2.80-3.03 for the period, compared to the Thomson Reuters consensus estimate of $2.85. The company issued revenue guidance of $524-545 million (Down 2% to Up 2%), compared to the consensus revenue estimate of $538.50 million.
What price target have analysts set for CBM?
3 brokerages have issued twelve-month price objectives for Cambrex's shares. Their forecasts range from $60.00 to $60.00. On average, they anticipate Cambrex's stock price to reach $60.00 in the next year. View Analyst Ratings for Cambrex.
Who are some of Cambrex's key competitors?
Some companies that are related to Cambrex include Advanced Accelerator Application (AAAP), Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Array BioPharma (ARRY), Tesaro (TSRO), Ultragenyx Pharmaceutical (RARE), Emergent BioSolutions (EBS), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Evotec A.G. (EVTCY), Clovis Oncology (CLVS), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Acadia Pharmaceuticals (ACAD) and Akorn (AKRX).
Who are Cambrex's key executives?
Cambrex's management team includes the folowing people:
- Mr. Steven M. Klosk, Pres, CEO & Director (Age 61)
- Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 52)
- Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 40)
- Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy (Age 52)
- Mr. Tom G. Vadaketh, Exec. VP & CFO (Age 55)
Has Cambrex been receiving favorable news coverage?
News articles about CBM stock have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cambrex earned a media sentiment score of 0.16 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.96 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Cambrex?
Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cambrex's stock price today?
One share of CBM stock can currently be purchased for approximately $54.70.
How big of a company is Cambrex?
Cambrex has a market capitalization of $1.81 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.
How can I contact Cambrex?
Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]
MarketBeat Community Rating for Cambrex (CBM)
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cambrex (NYSE:CBM) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Cambrex in the last 12 months. Their average twelve-month price target is $60.00, suggesting that the stock has a possible upside of 9.69%. The high price target for CBM is $60.00 and the low price target for CBM is $60.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $60.00 | $60.00 | $60.50 | $65.6667 |
| Price Target Upside: | 9.69% upside | 9.19% upside | 17.13% upside | 16.64% upside |
Cambrex (NYSE:CBM) Consensus Price Target History
Cambrex (NYSE:CBM) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Cambrex (NYSE:CBM) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cambrex (NYSE CBM) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.42%
Cambrex (NYSE CBM) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/2/2017 | Steven M Klosk | CEO | Sell | 4,000 | $54.96 | $219,840.00 | 87,328 |  |
| 9/1/2017 | Steven M Klosk | CEO | Sell | 12,000 | $51.53 | $618,360.00 | 95,328 | |
| 8/1/2017 | Steven M Klosk | CEO | Sell | 12,000 | $61.39 | $736,680.00 | 95,328 | |
| 7/3/2017 | Steven M Klosk | CEO | Sell | 12,000 | $59.66 | $715,920.00 | 95,328 | |
| 6/12/2017 | Samantha Hanley | VP | Sell | 14,000 | $57.56 | $805,840.00 | 1,500 | |
| 6/6/2017 | Leon J Hendrix Jr | Director | Sell | 20,656 | $55.95 | $1,155,703.20 | 74,662 | |
| 6/1/2017 | Steven M Klosk | CEO | Sell | 12,000 | $54.19 | $650,280.00 | 95,328 | |
| 5/1/2017 | Steven M Klosk | CEO | Sell | 12,000 | $58.20 | $698,400.00 | 95,328 | |
| 4/3/2017 | Steven M Klosk | CEO | Sell | 12,000 | $54.58 | $654,960.00 | 95,328 | |
| 3/1/2017 | Steven M Klosk | CEO | Sell | 12,000 | $56.70 | $680,400.00 | 95,328 | |
| 2/27/2017 | Shawn Cavanagh | COO | Sell | 19,620 | $55.95 | $1,097,739.00 | 17,658 | |
| 2/16/2017 | Steven M Klosk | CEO | Sell | 23,822 | $52.50 | $1,250,655.00 | 94,241 | |
| 2/13/2017 | Steven M Klosk | CEO | Sell | 63,178 | $52.55 | $3,320,003.90 | 109,062 | |
| 2/7/2017 | Gregory Sargen | EVP | Sell | 30,000 | $54.88 | $1,646,400.00 | 50,000 | |
| 2/7/2017 | Shawn Cavanagh | COO | Sell | 20,380 | $55.12 | $1,123,345.60 | 57,658 | |
| 12/14/2016 | Shawn Cavanagh | COO | Sell | 30,000 | $53.58 | $1,607,400.00 | 27,658 | |
| 11/11/2016 | Gregory Sargen | Insider | Sell | 22,500 | $52.02 | $1,170,450.00 | 27,500 | |
| 7/11/2016 | William B Korb | Director | Sell | 3,420 | $55.00 | $188,100.00 | 23,982 | |
| 6/8/2016 | William B Korb | Director | Sell | 4,142 | $52.47 | $217,330.74 | 24,704 | |
| 6/1/2016 | William B Korb | Director | Sell | 8,000 | $51.06 | $408,480.00 | 25,304 | |
| 5/9/2016 | Steven M Klosk | CEO | Sell | 14,005 | $49.00 | $686,245.00 | 147,333 | |
| 5/5/2016 | Steven M Klosk | CEO | Sell | 16,430 | $49.13 | $807,205.90 | 136,828 | |
| 5/3/2016 | William B Korb | Director | Sell | 8,000 | $49.09 | $392,720.00 | 32,562 | |
| 3/16/2016 | Steven M Klosk | CEO | Sell | 19,565 | $41.00 | $802,165.00 | 152,893 | |
| 3/15/2016 | Louis J Grabowsky | Director | Buy | 750 | $40.10 | $30,075.00 | 928 | |
| 3/10/2016 | William B Korb | Director | Sell | 8,000 | $41.38 | $331,040.00 | 32,562 | |
| 2/11/2016 | Gregory Sargen | CFO | Sell | 13,622 | $36.16 | $492,571.52 | 46,697 | |
| 2/11/2016 | Shawn Cavanagh | COO | Sell | 18,342 | $36.13 | $662,696.46 | 17,658 | |
| 2/11/2016 | Steven M. Klosk | CEO | Sell | 39,542 | $36.20 | $1,431,420.40 | 133,328 | |
| 12/15/2015 | Leon J. Hendrix, Jr. | Director | Sell | 7,000 | $51.34 | $359,380.00 | 71,211 | |
| 12/11/2015 | Peter G. Tombros | Director | Sell | 31,236 | $51.37 | $1,604,593.32 | 21,520 | |
| 11/30/2015 | Ilan Kaufthal | Director | Sell | 52,315 | $54.32 | $2,841,750.80 | 60,000 | |
| 11/13/2015 | Gregory Sargen | CFO | Sell | 28,750 | $49.14 | $1,412,775.00 | 33,319 | |
| 11/6/2015 | Samantha Hanley | VP | Sell | 15,000 | $52.03 | $780,450.00 | | |
| 8/27/2015 | William B. Korb | Director | Sell | 3,600 | $48.00 | $172,800.00 | 46,562 | |
| 5/21/2015 | Ilan Kaufthal | Director | Sell | 50,000 | $41.31 | $2,065,500.00 | | |
| 5/11/2015 | Gregory Sargen | CFO | Sell | 25,000 | $38.44 | $961,000.00 | | |
| 2/12/2015 | Aldo Magnini | Director | Sell | 7,500 | $32.75 | $245,625.00 | | |
| 2/12/2015 | Gregory Sargen | CFO | Sell | 25,000 | $32.64 | $816,000.00 | | |
| 2/10/2015 | Steven M Klosk | CEO | Sell | 45,000 | $30.32 | $1,364,400.00 | | |
| 9/11/2014 | Shawn Cavanagh | COO | Sell | 56,251 | $22.56 | $1,269,022.56 | | |
| 9/3/2014 | Steven M Klosk | CEO | Sell | 126,257 | $22.01 | $2,778,916.57 | | |
| 9/2/2014 | William M Haskel | SVP | Sell | 9,400 | $21.94 | $206,236.00 | | |
| 8/19/2014 | Steven M Klosk | CEO | Sell | 4,702 | $22.00 | $103,444.00 | | |
| 8/7/2014 | Steven M Klosk | CEO | Sell | 1,200 | $22.52 | $27,024.00 | | |
| 8/7/2014 | William M Haskel | SVP | Sell | 28,100 | $22.50 | $632,250.00 | | |
| 8/5/2014 | Gregory Sargen | CFO | Sell | 50,000 | $22.34 | $1,117,000.00 | | |
| 2/28/2014 | Leon Hendrix, Jr. | Director | Sell | 23,000 | $20.09 | $462,070.00 | 92,993 | |
| 2/20/2014 | Aldo Magnini | Director | Sell | 6,000 | $22.10 | $132,600.00 | | |
| 12/5/2013 | Paolo Russolo | Insider | Sell | 35,000 | $18.40 | $644,000.00 | 67,085 | |
| 11/11/2013 | Gregory Sargen | CFO | Sell | 20,000 | $18.92 | $378,400.00 | 33,319 | |
| 11/11/2013 | John Miller | Director | Sell | 2,000 | $19.21 | $38,420.00 | 35,306 | |
| 5/24/2013 | Paolo Russolo | Insider | Sell | 32,903 | $12.53 | $412,274.59 | | |
| 5/16/2013 | Leon J Hendrix Jr | Director | Sell | 1,120 | $13.40 | $15,008.00 | | |
(Data available from 1/1/2013 forward)
Cambrex (NYSE CBM) News Headlines
| Source: |
|
Cambrex (NYSE:CBM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cambrex (NYSE:CBM) Income Statement, Balance Sheet and Cash Flow Statement
Cambrex (NYSE CBM) Stock Chart for Monday, April, 23, 2018
Loading chart…
